CVE-2022-3389 json
Path Traversal in ikus060/rdiffweb
published 2022-10-06 4 y ago modified 2026-06-17 4 mo ago also GHSA-hrrm-895h-xh34 , PYSEC-2022-302 , EUVD-2022-0248
- cvss
- 8.2
- version 3.0, CNA
- cisa kev
- Not listed
- not in CISA's catalog
- epss
- 1.4%
- EPSS 1.4% chance of exploitation in 30 days, percentile 72%
- public exploits
- 0
- none known
Summary
Path Traversal in GitHub repository ikus060/rdiffweb prior to 2.4.10.
Patch / fix
Exploit prediction
1.39% chance of exploitation in the next 30 days, higher than 72% of all scored CVEs (FIRST EPSS, 2026-11-08).
Exploits and checks
- huntr.dev https://huntr.dev/bounties/f7d2a6ab-2faf-4719-bdb6-e4e5d6065752 referenced PoC, tagged "exploit" by a source, unverified
CVSS scores
| assigned by | version | score | vector |
|---|---|---|---|
| CNA | 3.0 | 8.2 | CVSS:3.0/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:L/A:N |
| NVD | 3.1 | 7.5 | CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N |
| GitHub | 3.1 | 7.5 | CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N |
Affected packages
| ecosystem | package | affected | fixed in |
|---|---|---|---|
| pypi | rdiffweb | <2.4.10 |
2.4.10 |
Affected products
- ikus060 ikus060/rdiffweb
Classification
- Weakness
-
- CWE-22 Improper Limitation of a Pathname to a Restricted Directory
References
-
github.com
/ikus060/rdiffweb/commit/323383d1db656f1b1291be529947bd943a6b0e99
web, patch, third-party-advisory
-
huntr.dev
/bounties/f7d2a6ab-2faf-4719-bdb6-e4e5d6065752
web, exploit, third-party-advisory, evidence
-
nvd.nist.gov
/vuln/detail/CVE-2022-3389
advisory
-
github.com
/ikus060/rdiffweb
package
-
github.com
/pypa/advisory-database/tree/main/vulns/rdiffweb/PYSEC-2022-302.yaml
web
-
github.com
/advisories/GHSA-hrrm-895h-xh34
advisory
Sources
- CVE List CVE-2022-3389
- GitHub Advisory GHSA-hrrm-895h-xh34
- NVD CVE-2022-3389
- OSV PYSEC-2022-302
Fencer Vulns keeps one entry per vulnerability: the CVE id wins, then GHSA, and records that alias each other are merged, except that two CVEs always keep separate entries. The same data is available as JSON.